Scientific basis for the combination of tegafur with uracil

Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Fujii et al reported that Uracil potentiated the antitumor activity of fluorouracil (5-FU) and 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur). This effect was due to inhibition of the degradation of 5-FU, yet the phosphorylation of 5-FU was unaffected. The molar ratio of tegafur and uracil was 1:4, a combination that has since been widely prescribed in Japan for the treatment of cancer patients. We present here our experimental and clinical results when investigating the antineoplastic effects of this combination of drugs - known as UFT - and provide evidence that UFT is an effective treatment for patients with cancer.

Original languageEnglish
Pages (from-to)14-21
Number of pages8
Issue number9 SUPPL. 10
Publication statusPublished - 1997

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Scientific basis for the combination of tegafur with uracil'. Together they form a unique fingerprint.

Cite this